Your browser doesn't support javascript.
loading
Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data.
Shetty, Arya; Wang, Su; Khan, A Basit; English, Collin W; Nouri, Shervin Hosseingholi; Magill, Stephen T; Raleigh, David R; Klisch, Tiemo J; Harmanci, Arif O; Patel, Akash J; Harmanci, Akdes Serin.
Afiliação
  • Shetty A; Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
  • Wang S; McGovern Medical School, Houston, TX, USA.
  • Khan AB; Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
  • English CW; Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
  • Nouri SH; Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
  • Magill ST; Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
  • Raleigh DR; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Klisch TJ; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Harmanci AO; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
  • Patel AJ; Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
  • Harmanci AS; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.
J Neurooncol ; 168(3): 515-524, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38811523
ABSTRACT

PURPOSE:

Accurate classification of cancer subgroups is essential for precision medicine, tailoring treatments to individual patients based on their cancer subtypes. In recent years, advances in high-throughput sequencing technologies have enabled the generation of large-scale transcriptomic data from cancer samples. These data have provided opportunities for developing computational methods that can improve cancer subtyping and enable better personalized treatment strategies.

METHODS:

Here in this study, we evaluated different feature selection schemes in the context of meningioma classification. To integrate interpretable features from the bulk (n = 77 samples) and single-cell profiling (∼ 10 K cells), we developed an algorithm named CLIPPR which combines the top-performing single-cell models, RNA-inferred copy number variation (CNV) signals, and the initial bulk model to create a meta-model.

RESULTS:

While the scheme relying solely on bulk transcriptomic data showed good classification accuracy, it exhibited confusion between malignant and benign molecular classes in approximately ∼ 8% of meningioma samples. In contrast, models trained on features learned from meningioma single-cell data accurately resolved the sub-groups confused by bulk-transcriptomic data but showed limited overall accuracy. CLIPPR showed superior overall accuracy and resolved benign-malignant confusion as validated on n = 789 bulk meningioma samples gathered from multiple institutions. Finally, we showed the generalizability of our algorithm using our in-house single-cell (∼ 200 K cells) and bulk TCGA glioma data (n = 711 samples).

CONCLUSION:

Overall, our algorithm CLIPPR synergizes the resolution of single-cell data with the depth of bulk sequencing and enables improved cancer sub-group diagnoses and insights into their biology.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Algoritmos / Análise de Sequência de RNA / Análise de Célula Única / Neoplasias Meníngeas / Meningioma Limite: Humans Idioma: En Revista: J Neurooncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Algoritmos / Análise de Sequência de RNA / Análise de Célula Única / Neoplasias Meníngeas / Meningioma Limite: Humans Idioma: En Revista: J Neurooncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos